Compare CMP & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMP | DRUG |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Pharmaceuticals and Biotechnology |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 707.1M |
| IPO Year | 2003 | 2020 |
| Metric | CMP | DRUG |
|---|---|---|
| Price | $21.73 | $71.32 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $21.50 | ★ $124.00 |
| AVG Volume (30 Days) | ★ 379.5K | 82.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.85 | N/A |
| P/E Ratio | $52.79 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.60 | $23.18 |
| 52 Week High | $27.00 | $123.75 |
| Indicator | CMP | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 35.56 |
| Support Level | $20.58 | $49.47 |
| Resistance Level | $26.40 | $91.00 |
| Average True Range (ATR) | 1.14 | 4.55 |
| MACD | -0.31 | -1.24 |
| Stochastic Oscillator | 12.72 | 9.05 |
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.